SCHEMBL5879262

SCHEMBL5879262

O=c1[nH]c(=O)c2c1c1[nH]c3cc(OCc4ccccc4)ccc3c1c1c(=O)[nH]c(=O)c21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 3/20 0.61
CTSL P07711 3/20 0.61
GABRA1 P14867 1/20 0.57
GABRG2 P18507 1/20 0.57
GABRB3 P28472 1/20 0.57
GABRA3 P34903 1/20 0.57
GABRA2 P47869 1/20 0.57
CHEK1 O14757 3/20 0.56
CDK4 P11802 2/20 0.56
CCND1 P24385 2/20 0.56
MAOA P21397 3/20 0.55
CCNE2 O96020 1/20 0.52
PRKACA P17612 1/20 0.52
PRKACG P22612 1/20 0.52
PRKACB P22694 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
TNKS2 Q9H2K2 1/20 0.49
PARP2 Q9UGN5 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879186 0.90 MAOA (0.58) CTSVCTSLGABRA1GABRG2GABRB3
SCHEMBL14422837 0.78 CHEK1 (0.63) CTSVCTSLGABRA1GABRG2GABRB3
SCHEMBL5879176 0.78 CTSV (0.63) CTSVCTSLCHEK1ALDH1A1HPGD
SCHEMBL5879202 0.76 CDK4 (0.62) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL177218 0.75 CTSV (0.62) CTSVCTSLMAOATNKS2PARP2
SCHEMBL14422827 0.75 CTSV (0.83) CTSVCTSLGABRA1GABRG2GABRB3
SCHEMBL2795363 0.75 CTSV (0.65) CTSVCTSLMAOATNKS2ALDH1A1
SCHEMBL17780933 0.74 CTSV (0.64) CTSVCTSLGABRA1GABRG2GABRB3
SCHEMBL5879271 0.74 ADORA3 (0.53) CTSVCTSLCHEK1ALDH1A1MAOB
SCHEMBL6421417 0.74 MAOB (0.81) CTSVCTSLMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CTSV 4382/4885CTSL 4574/4885GABRA1 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.